Highest-materiality recent filing
David Lowrance resigns as CFO & CAO eff. July 15, 2026 due to health; receives severance and 12-month equity vesting acceleration.
Savara signs lease for new HQ in Yardley, PA; 5-year term starting July 2026
Lease for 10,795 sq ft at 19 W. College Ave, Yardley, PA; term 7/1/2026 to 12/1/2031.
Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI
Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.
Savara updates corporate presentation; no material new disclosures
Corporate presentation posted on IR website and furnished as exhibit.
Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share
23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.
Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action
RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.
Savara updates corporate presentation; no material new disclosures
Updated corporate presentation posted on IR website and furnished as Exhibit 99.1.
Savara stockholders elect directors, ratify auditors, and approve say-on-pay at 2025 annual meeting
All six director nominees elected with at least 118.7 million votes in favor each.
Savara receives FDA Refusal to File for MOLBREEVI BLA; resubmission expected Q4 2025
FDA requested additional CMC data; RTF not due to safety or efficacy concerns.
Savara terminates ATM equity offering agreement with Evercore, effective April 2, 2025
Delivered notice to Evercore on March 31, 2025 terminating the ATM Agreement under Section 12(b).
Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close
$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.
Savara sets 2025 executive bonus targets; CEO bonus $330k, other execs $165k-$200k
CEO Matthew Pauls target bonus $330,000 (50% of base salary).
Savara updates corporate presentation; no material new information disclosed
Corporate presentation updated and posted on IR website on January 13, 2025.
Savara prices $100M common stock offering at $3.81/sh, 26.2M shares
Gross proceeds of ~$100M from 26,246,720 shares at $3.81 per share.
Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met
Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).
Savara stockholders approve 2024 Omnibus Incentive Plan adding 11.7M new shares
Stockholders approved 2024 Omnibus Incentive Plan at June 6, 2024 annual meeting.
Savara shareholders approve officer exculpation charter amendment and 2024 omnibus incentive plan
Amendment to certificate of incorporation allowing officer exculpation under Delaware law approved (88.6M for, 14.1M against).
Savara director Dr. Ricky Sun not to stand for reelection; Bain waives board designation right
Dr. Ricky Sun notified Board on April 10, 2024 of intention not to stand for reelection at 2024 Annual Meeting; will serve until then.
Savara enters master services agreement with Fujifilm for molgramostim manufacturing
Agreement covers development and manufacturing services for molgramostim active pharmaceutical ingredient.
CEO Matthew Pauls 2024 target bonus set at $310,000 (50% of base salary), fully tied to corporate performance.
Savara updates corporate presentation with no new material information
Corporate presentation furnished as Exhibit 99.1, available on Savara's website.
Savara prices $80M underwritten offering of common stock and pre-funded warrants at $3.00/share
Offering of 21M common shares at $3.00/share and 5.67M pre-funded warrants at $2.999/warrant for $80M gross proceeds.
Savara stockholders elect all director nominees, approve 3M share increase at annual meeting
All seven director nominees elected with >66M votes for each; Nevan Elam received 66.7M for, 15.7M against.
Savara updates corporate presentation; no material new disclosures
Updated corporate presentation posted on IR page and furnished as Exhibit 99.1.
Savara amends bylaws to update stockholder proposal and director nomination procedures
Added updated procedures for stockholder proposals and director nominations, including additional information requirements.
Savara says SVB closure exposure immaterial; >99% of cash held elsewhere
Savara discloses its exposure to Silicon Valley Bank closure is immaterial.
Savara expands Langhorne office lease, relocates HQ
Amended lease adds 3,970 sq ft to current 2,465 sq ft office in Langhorne, PA.
Savara appoints Robert Lutz as COO with $437K salary, $115K signing bonus
Robert Lutz, former CFO/COO of iBio and Strongbridge, joins Savara as COO effective Feb 13, 2023.
Savara appoints Dave Lowrance as CFO & CAO; enters amended CEO/CFO employment agreements
CEO Matt Pauls amended agreement: $595k base salary, 50% target bonus, enhanced severance.
Savara CMO Dr. Badrul Chowdhury resigns effective Sept. 9, 2022
Dr. Badrul Chowdhury resigned as Chief Medical Officer, effective September 9, 2022.
Savara shareholders elect 8 directors, approve equity plan amendment at annual meeting
All 8 director nominees elected; Matthew Pauls led with 65.3M votes for, 379K against.
Savara enters $26.5M term loan facility with Silicon Valley Bank; refinances prior debt
Amended and restated loan agreement provides $26.5M term loan, refinancing all outstanding obligations under prior facility.
Savara approves 2022 target bonuses: CEO $290K (50% base), CMO $219.5K (40%), CFO $166.7K (40%)
CEO Pauls target bonus $290,000 (50% of base); 100% corporate performance measures.
Savara updates corporate presentation; no specific financial or clinical data disclosed in filing
Corporate presentation furnished as Exhibit 99.1, available on Savara's IR website.
Savara enters $60M at-the-market equity offering program with Evercore
Savara signs Sales Agreement with Evercore to sell up to $60M of common stock in ATM offerings.
Mr. Lutz's appointment follows the decision of David Lowrance to resign from his role as Savara's Chief Financial and Administrative Officer, effective as of the Effective Date, due to health reasons.
On June 5, 2026, the Board appointed Robert Lutz to become the Chief Financial and Operating Officer of Savara effective July 15, 2026 (the "Effective Date").
On April 10, 2024, Dr. Ricky Sun notified the Board of Directors (the “Board”) of Savara Inc. (the “Company”) of his intention not to stand for reelection to the Board following the expiration of his current term at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
On February 13, 2023 (the “Effective Date”), Robert Lutz joined Savara Inc. (“Savara”) as its Chief Operating Officer.
On the Effective Date, the Board of Directors (the “Board”) of Savara appointed Dave Lowrance, who has served as Savara’s Chief Financial Officer since November 2016, as Chief Financial and Administrative Officer of Savara.
On August 24, 2022, Dr. Badrul Chowdhury notified Savara Inc. (“Savara”) of his decision to resign as Chief Medical Officer of Savara.
Max materiality 0.90 · Median 0.40 · Most common event other_material